Innovative drugs accelerate, innovative medicine ETF (159992) leads the market, Kangtai Biological Leading Rate

On September 27, the innovative pharmaceutical sector rose a lot.My martial arts biological leadership, Hylco and Kangtai biological increased, innovative drug ETF (159992) transactions are relatively active, and the current transaction volume has exceeded 200 million.

Soochow Securities said that the international status of domestic innovative drugs has increased year by year.On the one hand, the amount and quantity of local innovation drugs have repeatedly reached a record high. As of the first half of 2022, more than 70 domestic innovative drugs went to sea in the form of Licenseout, including billions of dollars of heavy transactions.On the other hand, with China's innovation capabilities and overseas clinical capabilities, more and more innovative pharmaceutical companies have begun to carry out international clinical clinical, including Zabitinib (anti -cancer), and radarbing.Tumor) and other products have carried out a series of global multi -center clinical trials.As more and more local innovative pharmaceutical companies carry out MRCT in accordance with the rules of the FDA, and always maintain communication with the FDA, more local innovative drugs will be listed in the United States in the future to share the overseas innovative drug market dividends.

- END -